世界の幹細胞技術市場展望：2012年〜2022年

※ このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

Report Details

Why the stem cells market will expand - discover its commercial potential

What does the future hold for stem cells in medicine? Visiongain's report shows you potential revenues to 2022, assessing data, trends, opportunities and prospects there.

That new study lets you assess projected sales at world market and submarket level. You see discussions of work on stem cells in leading countries too - outlooks, challenges, patenting and regulations.

You see forecasting of world-level submarkets to 2022, finding potential revenues:

• Stem cell therapies
• Stem cell banks (e.g., cord blood banking)
• Ancillaries - adjunct technologies.

The technology is changing medicine through new therapies, methods and applications in drug development. Its scope is vast and promising, despite challenges.

With our study you also assess the R&D pipeline, seeing trends and outlooks. You find discussions of treatments in development, by therapeutic area and organisation:

• Autoimmune diseases - modifying the immune system
• Diabetes - restoring pancreatic function
• Oncology and cancer treatment
• Cardiovascular diseases - healing the heart and vascular system
• Neurological and cerebrovascular disorders - regenerating CNS tissue
• Ophthalmic disorders - potential for overcoming sight loss
• Bioartificial livers and hepatic regeneration with stem and progenitor cells
• Dermatology - developments in cellular skin repair
• Adipose-derived stem cells for autologous treatments
• Regenerative dentistry - potential for biotechnological tooth replacement.

You find prospects for embryonic, adult and induced pluripotent stem cells from 2012.

Market value for 2014 and prospects for the future

What will happen next? The biotechnology industry will develop many products using stem cells and increase revenues there from 2012 to 2022. The R&D pipeline is extensive. Overall world revenue will reach $7.3bn in 2014, our report forecasts.

Expansion of the market will result from new stem cell treatments and increased uptake of those technologies in drug development assays.

A diverse pipeline of therapies offers hope for treating many diseases. There are potential cures for diabetes, HIV and dry age-related macular degeneration (AMD).

Stem cell-based innovations tackle cardiovascular disorders, autoimmune diseases, metabolic disorders and many other conditions. Some of the breakthroughs will be a commercial reality by 2022, our investigation predicts.

What are companies doing? Our work profiles 187 organisations and investigates prospects of the industry and market. Examples include these developers and producers:

• Advanced Cell Technology
• Athersys
• Baxter Healthcare
• Bioheart
• Cytori Therapeutics
• Gamida Cell
• Mesoblast
• NeoStem
• Osiris Therapeutics
• TiGenix.

The scope of the field is widening, with many organisations entering and collaborating. You see how.

Haematopoietic stem cell transplantation is an established treatment. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012. Those activities form a beginning, with many advances possible by 2020.

There are many commercial opportunities in stem cells, with high revenues possible from 2012 to 2022. New products will change medicine. Our report shows you and explains.

Forecasts, market shares, developmental trends, commercial news and discussions

In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles and discussions of R&D activities. You receive 40 tables, 20 charts and six research interviews.

Eight ways Stem Cell Technologies: World Market Outlook 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:

• Find potential revenues to 2022 for the overall world market and submarkets
• Assess 187 prominent organisations, discovering activities and outlooks
• See discussions of stem cell work in the US, the UK, other prominent European countries, Israel, Japan, India, China and South Korea
• Review R&D pipelines, seeing trends and progress by therapeutic area
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• Analyse prospects for established companies and those seeking to enter the sector
• View opinions from our survey, seeing interviews with authorities.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Without our report you could miss out on information that your competitors use.

Table of Contents

1. Executive Summary

• 1.1 Overview of Findings
• 1.2 Chapters in the Report
• 1.3 Research and Analysis Methods

2. Stem Cells: An Introduction

• 2.1 What Are Stem Cells?
• 2.2 Potency and Differentiation
• 2.3 Embryonic Stem Cells
• 2.4 Adult Stem Cells
  • 2.4.1 Haematopoietic Stem Cells
  • 2.4.2 Mesenchymal Stem Cells
  • 2.4.3 Adipose-Derived and Other Stromal Stem Cells
  • 2.4.4 Neural Stem Cells
  • 2.4.5 Other ASCs
• 2.5 Induced Pluripotent Stem Cells
• 2.6 Autologous and Allogeneic Properties
• 2.7 Stem Cells in Medicine: Past, Present and Future

3. The World Stem Cells Market 2012-2022: Overview

• 3.1 The Stem Cells Market, 2012
• 3.2 Stem Cells Market Forecast 2012-2022
• 3.3 Stem Cells Market Segmentation
• 3.4 What is a Stem Cell Therapy?
• 3.5 Stem Cells, Progenitor Cells, Cellular Therapies, and Regenerative Medicine
• 3.6 What is a Stem Cell Product? A Note on the Stem Cell Transplant Market

4. Stem Cell Therapies Market, 2012-2022

• 4.1 World Market Forecast, 2012-2022
• 4.2 Existing Stem Cell Therapies, 2012
• 4.3 Haematopoietic Stem Cell Transplantation Market, 2012
  • 4.3.1 Therapeutic Effectiveness of Stem Cell Transplantation
  • 4.3.2 Graft Versus Host Disease and Other Factors in Stem Cell Transplantation
• 4.4 World Stem Cell Treatments Market, 2012
• 4.5 Stem Cell Orthobiologics, 2012
  • 4.5.1 The Use of Stem Cells in Orthobiologics
  • 4.5.2 NuVasive - the Osteocel Product Family
  • 4.5.3 Orthofix - The Trinity Bone Matrix
  • 4.5.4 Osteotech - Harvesting Autologous Bone Marrow Stem Cells
  • 4.5.5 Skye Orthobiologics - Soft Tissue Repair with a Cellular Matrix
  • 4.5.6 SpineSmith - Point-of-Care Bone Marrow Cells for the Spine
  • 4.5.7 RTI Biologics - Rolling Out Stem Cell Orthobiologics from 2012?
  • 4.5.8 BioMet Orthopedics - Trialling the MarrowStim Concentration Kit
  • 4.5.9 MedCell Bioscience - Tendon Therapies
  • 4.5.10 Banc de Sang i Teixits - Bone Repair in Catalonia
  • 4.5.11 Apatech - Observing Outcomes for Stem Cell Grafts
  • 4.5.12 Other Companies in Stem Cell Orthobiologics
• 4.6 Other Approved Stem Cell Products, 2012
  • 4.6.1 FCB-Pharmicell - Hearticellgram-AMI, the First Approved Product of its Kind
  • 4.6.2 Anterogen - Cupistem, Adipose-Derived Stem Cells for Anal Fistula
  • 4.6.3 Medipost - Cartistem
• 4.7 Late-Stage Pipeline for Stem Cell Therapeutics
  • 4.7.1 Aastrom Biosciences - Ixmyelocel-T for Critical Limb Ischemia
  • 4.7.2 Gamida Cell - StemEx: A Cord Blood Blockbuster?
  • 4.7.3 Mesoblast - 40-Fold Expansion of Cord Blood Stem Cells
  • 4.7.4 Osiris Therapeutics - Prochymal
  • 4.7.5 Baxter Healthcare - Autologous CD34 Positive Cells for Heart Disease
  • 4.7.6 TiGenix - Cx601 for Complex Perianal Fistula
  • 4.7.7 Bioheart - MyoCell in MARVEL Trial
  • 4.7.8 Cytori Therapeutics - Adipose-Derived Cells for Acute Myocardial Infarction
  • 4.7.9 Stempeutics Research - First Stem Cell Approval in the Indian Market?
• 4.8 Pipeline for Stem Cell Transplantation Ancillary Products
  • 4.8.1 Mobilisation/Engraftment / Graft Enhancement
    • 4.8.1.1 Bayer - GM-CSF for Mobilisation and other Trials
    • 4.8.1.2 Biokine Therapeutics - BKT140 for Stem Cell Mobilisation and Myeloma Cell Destruction
    • 4.8.1.3 Biothera - Imprime PGG for Progenitor Mobilisation
    • 4.8.1.4 Celldex Therapeutics - CDX-301 Protein to Enhance Harvesting
    • 4.8.1.5 Cytheris - Interleukin-7 for Immune Reconstitution
    • 4.8.1.6 Eisai - Treatments for Sepsis, Nausea and Immune Enhancement
    • 4.8.1.7 Fate Therapeutics - ProHema for Pharmacological Enhancement
    • 4.8.1.8 Genzyme - Plerixafor in Label-Extension Trials
    • 4.8.1.9 Noxxon Pharma - Spiegelmers for Mobilisation
    • 4.8.1.10 Shenzhen Zhongxing Yangfan Biotech - Ex Vivo Activated Immune Cells
    • 4.8.1.11 Systemix - RevM10 Gene Therapy Trial
    • 4.8.1.12 Polyphor - Small Molecule Mobilisation Enhancement
    • 4.8.1.13 TaiGen Biotechnology - Burixafor for Stem Cell Mobilisation
    • 4.8.1.14 Tarix Pharmaceuticals - TXA127 Peptide for Peripheral Stem Cell Populations
    • 4.8.1.15 Xcyte Therapies - Xcellerate Technology for Improving Implantation Outcomes
  • 4.8.2 Anti-Graft versus Host Disease
    • 4.8.2.1 Alder Biopharmaceuticals - ALD518 Antibody
    • 4.8.2.2 AstraZeneca - MEDI-507 for Paediatric Patients
    • 4.8.2.3 Fresenius Biotech - Polyclonal Antibody for Prophylaxis
    • 4.8.2.4 Kiadis Pharma - ATIR for Allogeneic Transplant Enhancement
    • 4.8.2.5 MolMed - Genetically Engineering Lymphocytes
    • 4.8.2.6 PDL BioPharma - Visilizumab in Trials
    • 4.8.2.7 Rafa Laboratories - Budesonide as New Steroid Option
    • 4.8.2.8 Regimmune - Immunomodulator for Allogeneic Transplants
    • 4.8.2.9 Therakos - Photophoresis of Peripheral Blood Cells
  • 4.8.3 New Anti-Infectives
    • 4.8.3.1 AM-Pharma - Antifungal Peptide Trials
    • 4.8.3.2 Astellas Pharma - Micafungin for Paediatric Transplant Recipients
    • 4.8.3.3 Cell Medica - Antiviral Cell Therapies
    • 4.8.3.4 Chimerix - CMX001 Targets Cytomegalovirus
    • 4.8.3.5 Enzon Pharmaceuticals - Anti-Infective Recombinant Lectin Concept
    • 4.8.3.6 Gilead Sciences - AmBisome as Allogeneic Adjunct
    • 4.8.3.7 Johnson & Johnson - Janssen Trialling Antifungal Prophylaxis
    • 4.8.3.8 Merck & Co. - Antifungals for Allogeneic Transplant Assistance
    • 4.8.3.9 Vical - Cytomegalovirus Vaccine Candidate
    • 4.8.3.10 ViroPharma - Maribavir Antiviral in Phase III
    • 4.8.3.11 Xiamen Amoytop Biotech - Biological Anti-Infectives from Shanghai
  • 4.8.4 New Treatments for Combination
    • 4.8.4.1 Abbott - Leuprolide Acetate Depot in Haematological Malignancies
    • 4.8.4.2 AiCuris - AMD3100 in Trials with Busulfan and Other Combinations
    • 4.8.4.3 Alizyme - ATL-104 Targets Mucous Membrane Inflammation
    • 4.8.4.4 Biogen Idec - Combining Radio-Immunotherapy with Transplantation
    • 4.8.4.5 Celator Pharmaceuticals - Acute Myelogenous Leukaemia Candidate
    • 4.8.4.6 CyDex Pharmaceuticals - New Chemotherapeutics in Development
    • 4.8.4.7 Incyte - JAK Inhibitor for Haematological Malignancies
    • 4.8.4.8 Medac - Specialising in the Malignancies Segment
    • 4.8.4.9 Molecular Insight Pharmaceuticals - Iodine-131 Radio-Immunoconjugate Trial
    • 4.8.4.10 Otsuka Pharmaceutical Development & Commercialization - Further Busulfan Trials
    • 4.8.4.11 Pierre Fabre Medicament - Radiotherapy and Chemotherapy Combinations
    • 4.8.4.12 Poniard Pharmaceuticals - Radiation Treatments
    • 4.8.4.13 Swedish Orphan Biovitrum - Oral Mucositis Candidate
    • 4.8.4.14 Spectrum Pharmaceuticals - More Zevalin Combinations
    • 4.8.4.15 TAP Pharmaceutical Products - Secondary Amenorrhea in Transplant Patients
    • 4.8.4.16 Vion Pharmaceuticals - New Alkylating Agent

5. Medium and Long-Term Stem Cell Therapies Pipeline, 2012

• 5.1 Overview of the Stem Cell Pipeline, 2012
• 5.2 Oncology: Cancer Stem Cells and Other New Treatment Possibilities
  • 5.2.1 Amgen: Cell Transplantation for Metastatic Renal Cell Carcinoma
  • 5.2.2 Cellerant Therapeutics - Engraftment Enhancement and a Cancer Stem Cell Antibody
  • 5.2.3 ImmunoCellular Therapeutics - Glioblastoma Stem Cell Target
  • 5.2.4 Immunovative Therapies - Mirroring the Stem Cell Transplantation Anticancer Effect
  • 5.2.5 Novartis Pharmaceuticals - Cord Blood Transplant Candidate
  • 5.2.6 Ribozyome - Stem Cell Gene Therapy Concept for Hodgkin's Lymphoma
• 5.3 Autoimmune Diseases - Using Stem Cells to Reset the Immune System
  • 5.3.1 Alliancells Bioscience Corporation - Possible Rheumatoid Arthritis Treatment
  • 5.3.2 AlloCure - AC607 for Anti-Inflammatory Effects
  • 5.3.3 Athersys - MultiStem for Autoimmune and Other Disorders
  • 5.3.4 Celgene Corporation - Placental Tissue Stem Cells for Rheumatoid Arthritis and Others
  • 5.3.5 HomeoTherapy - Mesenchymal Stem Cells for GvHD
  • 5.3.6 ViroMed - Stem Cell Gene Therapy for Chronic Granulomatous Disease
• 5.4 Diabetes - Stem Cells to Restore Pancreatic Function
  • 5.4.1 Cellonis Biotechnology - Commercializing Peking University Research on Stem Cells in Diabetes
  • 5.4.2 Ixion Biotechnology - Liver Stem Cells for Insulin Production
  • 5.4.3 MaRS Innovation - Diabetes Partnership with Mount Sinai Hospital
  • 5.4.4 ViaCyte - Encaptra System for ESC-Produced Pancreatic Precursors
• 5.5 Cardiological/Cardiovascular Diseases - Stem Cells to Heal the Heart and Vascular System
  • 5.5.1 Aldagen - Proprietary Cells for Ischemic Conditions
  • 5.5.2 Apceth - Mesenchymal Stem Cells for Advanced Peripheral Arterial Occlusive Disease
  • 5.5.3 Athersys - Angiotech Collaboration
  • 5.5.4 Biogenea-Cellgenea - Cardiogenea for Myocardial Infarction
  • 5.5.5 Capricor - Using Cardiosphere-Derived Cells for Heart Repair
  • 5.5.6 Cardio3 Bioscience - Cardiopoiesis Platform for Heart Regeneration
  • 5.5.7 Cardiogenesis Corporation - Lasers and Stem Cells for Revascularisation
  • 5.5.8 Eli Lilly and Company: Collaborating on Intracoronary Injection of Progenitor Cells Trial
  • 5.5.9 Garnet BioTherapeutics - GBT009 for Cardiac Tissue Preservation
  • 5.5.10 Medistem - Endometrial Regenerative Cells for Critical Limb Ischemia
  • 5.5.11 Neostem - AMR-001 for Myocardial Infarction
  • 5.5.12 Northern Therapeutics - Gene Therapy for Pulmonary Arterial Hypertension
  • 5.5.13 OrbusNeich - Coronary Stent Activates Endogenous Cell Populations
  • 5.5.14 Pluristem Therapeutics - Placental Stem Cells for Peripheral Artery Disease
  • 5.5.15 Regenetech - Heart Disease Treated with NASA-Derived Tissue Technology
  • 5.5.16 TCA Cellular Therapy - Mesendo Autologous Treatments
• 5.6 Neurological/Cerebrovascular Disease - Regenerating Brain, Nerves and Vasculature
  • 5.6.1 New Paradigms in Neurodegenerative Disease Treatment
  • 5.6.2 BrainStorm Cell Therapeutics - NurOwn Cells for Spinal Cord Injury and ALS
  • 5.6.3 Corestem - Autologous Bone Marrow Stem Cells for ALS
  • 5.6.4 Geron Corporation - ESC Pioneer
  • 5.6.5 Neuralstem - Neural Stem Cells for Synaptic Repair and Neuroprotection
  • 5.6.6 NeuroGeneration - Parkinson's Treatment with Autologous Neural Stem Cells
  • 5.6.7 NsGene - Encapsulated Cell Biodelivery System
  • 5.6.8 Proneuron Biotechnologies - CNS Cellular Therapies
  • 5.6.9 ReNeuron - Foetally-Derived CTX Cells for Stroke
  • 5.6.10 Renovo Neural - Cellular Multiple Sclerosis Treatments
  • 5.6.11 RhinoCyte - Stem Cells from the Nasal Passage to the Spinal Cord
  • 5.6.12 Saneron CCEL Therapeutics - U-CORD-CELL Preclinical Platform
  • 5.6.13 StemCells - Clinical Trials in Batten Disease and Others
  • 5.6.14 Stem Cell Therapeutics - NTx-265 for Stroke
  • 5.6.15 SanBio - SB623 for Ischemic Stroke
  • 5.6.16 Stemedica Cell Technologies - Ischemic Tolerant Stem Cell Platform
  • 5.6.17 Theradigm - Neural Cells for CNS Disorders
  • 5.6.18 Titan Pharmaceuticals - Dopaminergic Cell Treatment Concept
• 5.7 Ophthalmic Disease - Chief Focus for ESC Clinical Work
  • 5.7.1 ArBlast - Treating Corneal Disorders and Other Diseases
  • 5.7.2 Advanced Cell Technology - Leading the Field in ESC Clinical Trials
  • 5.7.3 Biotime - Targeting AMD with ESCs
  • 5.7.4 CellSeed - CAOMECS for Cornea Repair
  • 5.7.5 Pfizer - Collaborating on the London Project to Cure Blindness
• 5.8 Other Areas of Investigation for Stem Cell Therapies
  • 5.8.1 Alliqua - HepaMate Bioartificial Liver and Stem Cells
  • 5.8.2 CellTran - Cellular Skin Repair Products
  • 5.8.3 GlaxoSmithKline - Collaborating with Harvard Stem Cell Institute
  • 5.8.4 Histogen - Hair Stimulating Complex Contains Stem Cell Factor
  • 5.8.5 IntelliCell Biosciences - Adipose-Derived Stem Cells for Autologous Treatments
  • 5.8.6 Intercytex - Formerly Owned Axordia Stem Cell Research
  • 5.8.7 iPierian - IPSC Expertise
  • 5.8.8 Medtronic - Links to MG Biotherapeutics and Tengion
  • 5.8.9 Odontis - BioTooth for Dental Replacement Concept
  • 5.8.10 Roche - Research Collaborations in the Field
  • 5.8.11 S-Evans Biosciences - Menstrual Stem Cells for Hepatic Disease
  • 5.8.12 Tengion - Neo-Organs from Progenitor Cells
  • 5.8.13 Tissue Genesis - First Point-of-Care Study of Adipose-Derived Stem Cells to be FDA-Approved
  • 5.8.14 Vesta Therapeutics - Regenerating the Liver with Stem and Progenitor Cells

6. Stem Cell Banking Market, 2012-2022

• 6.1 World Market Forecast, 2012-2022
• 6.2 Health Insurance for the Cellular Therapy Century: Overview of the Stem Cell Banking Field
• 6.3 Selected Companies in the Stem Cell Banking Field
  • 6.3.1 Amstem Corporation - Former Leader in the Field
  • 6.3.2 China Cord Blood Corporation - China's Biggest Blood Bank
  • 6.3.3 Cord Blood America - Presence in the US, Latin America and Europe
  • 6.3.4 Cryo-Cell - First Private Cord Blood Bank
  • 6.3.5 CryoCord - Leaders in Malaysia
  • 6.3.6 Cryo-Save - Europe's Largest Stem Cell Bank
  • 6.3.7 General BioTechnology - Stem Cells for Banking and Veterinary Therapies
  • 6.3.8 InSCeption Biosciences - Canada's Biggest Cord Blood Programme
  • 6.3.9 International Stemcell Services - First Indian Umbilical Cord Blood Bank
  • 6.3.10 LifebankUSA - First Transplanted Placental Cells
  • 6.3.11 Lifebank Cryogenics - Canada's First Cord Blood Bank
  • 6.3.12 Stem Cell Authority - Banking Mesenchymal Cells
  • 6.3.13 Stem Cell Sciences - Banking Adult Haematopoietic Stem Cells
  • 6.3.14 StemCyte - High Stem Cell Yield
  • 6.3.15 ViaCell - ViaCord Umbilical Cord Blood Bank

7. Stem Cell Ancillaries Market, 2012-2022

• 7.1 World Market Forecast, 2012-2022
• 7.2 Overview of Stem Cell-Related Business Models, 2012
• 7.3 Stem Cell Assays: An Important Field
  • 7.3.1 Axiogenesis - In Vitro Disease Models
  • 7.3.2 Cellectis Group - First Marketed Cardiomyocytes and Hepatocytes Derived from ESCs
  • 7.3.3 Cellular Dynamics International - Leader in IPSC Technology
  • 7.3.4 CXR Biosciences - Drug Development and Toxicology Services
  • 7.3.5 Maxcyte - Stem Cells in Early Phase Drug Discovery
  • 7.3.6 Stemina Biomarker Discovery - ESCs and Metabolomics
• 7.4 Stem Cell Supply and Processing: Products and Services
  • 7.4.1 3DM - PuraMatrix for Cell Culturing
  • 7.4.2 Adistem - Extraction and Activation Technology Platform
  • 7.4.3 AllCells - Stem Cell Line Supplier
  • 7.4.4 Angel Biotechnology - Stem Cell Contract Biomanufacturing
  • 7.4.5 Antria - Regenerative Medicine Contract Research Organisation
  • 7.4.6 Arteriocyte - Nanex Culturing and Expansion Technology
  • 7.4.7 BioE - Marketing the First Multipotent Clonal Stem Cell Line from Umbilical Cord Blood
  • 7.4.8 Bio-Matrix Scientific Group - Stem Cell Cryobanking, Research and Partnerships
  • 7.4.9 Cognate BioServices - Custom Manufacture and Testing of Stem Cells
  • 7.4.10 EpiStem - Epithelial Stem Cell Specialists
  • 7.4.11 FortiCell Bioscience - Biomaterials Technology Platforms
  • 7.4.12 Global Stem - Growth Media, Reagents and Other Stem Cell Tools
  • 7.4.13 Miltenyi Biotec - MACSQuant Analyzer and Other Stem Cell Tools
  • 7.4.14 Plasticell - CombiCult Differentiation Platform
  • 7.4.15 Roslin Cellab - ESC Lines and Other Resources
  • 7.4.16 StemCell Technologies - Stem Cell Culturing, Isolation, Training and Other Services
  • 7.4.17 StemCore - Pluripotent Cell Lines and Outsourcing Services
  • 7.4.18 Stemride International - Normal and Abnormal ESC Lines
  • 7.4.19 Vitro Biopharma - Tools for Stem Cell and Drug Development
• 7.5 Supporting Technologies
  • 7.5.1 BioLife Solutions: HypoThermosol and CryoStor Biopreservation
  • 7.5.2 CellCentric: Epigenetics and Cell Reprogramming Expertise
  • 7.5.2.1 Stem Cells and Epigenetics: Brief Discussion
  • 7.5.3 CellCyte Genetics - CCG-E45 Culture Chamber
  • 7.5.4 Covance - Heavy Involvement with Biological Drug Development
  • 7.5.5 ThermoFisher Scientific - Instruments, Equipment, Software and Other Medical Technology
  • 7.5.6 ThermoGenesis - BioArchive System and Other Proprietary Technologies

8. Stem Cells Market Regional Overview 2012

• 8.1 US: Controversy and Venture Capital
• 8.2 UK: Leading the Way in Europe
• 8.3 Europe: Mixed Responses
• 8.4 Israel: A Nexus of Stem Cell Innovation
• 8.5 Japan: Home of IPSC Research
• 8.6 India: High Activity in the Field
• 8.7 China: A Potential Leader in Stem Cells
• 8.8 South Korea: First to Approve Stem Cell Treatments

9. Main Research Interviews from Our Survey

• 9.1 Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine (CIRM)
  • 9.1.1 Current Stem Cell Clinical Trials
  • 9.1.2 Big Pharma Investment in Stem Cells
  • 9.1.3 Mesenchymal Cells in Clinical Trials
  • 9.1.4 Definitions of Cell Types and Regulatory Pathways
  • 9.1.5 The Prospects for Stem Cell Cures
• 9.2 Interview with Nick Bassil, Partner, Kilburn & Strode LLP
  • 9.2.1 Overview of the Stem Cell Patent Landscape
  • 9.2.2 The Aftermath of the Brustle Case
  • 9.2.3 Details and Consequences of the Brustle Ruling
  • 9.2.4 Patenting Adult Stem Cells and Induced Pluripotent Stem Cells
  • 9.2.5 Stem Cell Regulation and Stem Cell Ethics
• 9.3 Interview with Dr Kieran Breen, Director of Research and Innovation, Parkinson's UK
  • 9.3.1 Damage to Neural Matter Caused by Parkinson's Disease
  • 9.3.2 The Limitations for Stem Cell Treatment of Parkinson's Disease
  • 9.3.3 The Therapeutic Prospects for Induced Pluripotent Stem Cells
  • 9.3.4 The Likelihood of a Sustained Response to Regenerative Treatments of Parkinson's Disease
• 9.4 Interview with Jason Kolbert, MBA, Vice President of Strategic Business Development, NeoStem
  • 9.4.1 NeoStem's Business Model
  • 9.4.2 NeoStem's AMR-001 Candidate
  • 9.4.3 The Regulatory and Commercial Challenges for AMR-001
  • 9.4.4 NeoStem's VSEL and Blood Banking Platforms
  • 9.4.5 The Broader Stem Cell Therapies Market to 2022
• 9.5 Interview with Mr Felix von Haniel, Director, Business Development, Axiogenesis
  • 9.5.1 Axiogenesis' Tissue Production Platform
  • 9.5.2 Modelling Cardiac Hypertrophy
  • 9.5.3 Future Trends in the Stem Cells Assays Market
  • 9.5.4 The Potential for iPSCs

10. Conclusions

• 10.1 Strengths: Stem Cells Have Proven Clinical and Commercial Value
• 10.2 Weaknesses: The Field is Still in its Infancy
• 10.3 Opportunities: A Revolution in Medicine?
• 10.4 Threats: A Controversial Field
• 10.5 Concluding Remarks

List of Tables

• Table 2.1 Potency and Source of Stem Cells
• Table 2.2 Germ Layers and Their Associated Types of Cells and Organs
• Table 2.3 Sources of Stem Cells for Medical Applications, 2012
• Table 3.1 Stem Cells Market by Segment: Revenues ($m), Market Shares (%), 2011
• Table 3.2 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016
• Table 3.3 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2022
• Table 4.1 Stem Cell Therapies Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
• Table 4.2 Stem Cell Therapies Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
• Table 4.3 Medicare Coverage for HSCT, 2012
• Table 4.4 Malignancies and Other Haematological Diseases Treated with HSCT, 2012
• Table 4.5 Comparative Characteristics of Bone Marrow, Peripheral Blood and Cord Blood for HSCT, 2012
• Table 4.6 Orthobiologics Market: Segment Revenues ($bn) and Market Shares (%), 2011
• Table 4.7 Selected Players in Stem Cell Orthobiologics
• Table 4.8 Companies with Stem Cell Products Approved by the Korean FDA
• Table 4.9 Selected Approved (Non-Stem Cell) Cellular Therapies, 2012
• Table 4.10 Stem Cell Therapies in Phase III Development, 2012
• Table 4.11 Selected Non-Industry Sponsored Phase III Stem Cell Trials, 2012
• Table 4.12 Aastrom Biosciences' Currently-Listed Clinical Trials Involving Stem Cells, 2012
• Table 4.13 Gamida Cell's Currently-Listed Clinical Trials Involving Stem Cells, 2012
• Table 4.14 Mesoblast's Currently-Listed Clinical Trials Involving Stem Cells, 2012
• Table 4.15 Osiris Therapeutics' Currently-Listed Clinical Trials Involving Stem Cells, 2012
• Table 4.16 Baxter Healthcare's Currently-Listed Clinical Trials Involving Stem Cells, 2012
• Table 4.17 Cellerix's Currently-Listed Clinical Trials Involving Stem Cells, 2012
• Table 4.18 Bioheart's Currently-Listed Clinical Trials Involving Stem Cells, 2012
• Table 4.19 Cytori Therapeutics' Currently-Listed Clinical Trials Involving Stem Cells, 2012
• Table 4.20 Stempeutics Research's Currently-Listed Clinical Trials Involving Stem Cells, 2012
• Table 4.21 Selected Companies with Candidate Stem Cell Transplantation Ancillary Products, 2012
• Table 5.1 Quantity of Stem Cell Clinical Trials by Indication, 2012
• Table 5.2 Selected Companies Developing Stem Cell Treatments for Cancer, 2012
• Table 5.3 Selected Companies Developing Stem Cell Autoimmune Treatments, 2012
• Table 5.4 Selected Companies Developing Stem Cell Diabetes Treatments, 2012
• Table 5.5 Selected Companies Developing Stem Cell Cardiological/Cardiovascular Treatments, 2012
• Table 5.6 Selected Companies Developing Stem Cell Neurological/Cerebrovascular Treatments, 2012
• Table 5.7 Selected Companies Developing Stem Cell Ocular Treatments, 2012
• Table 6.1 Stem Cell Banking Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
• Table 6.2 Stem Cell Banking Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
• Table 6.3 Reported Fees of Various Private Stem Cell Blood Banks Worldwide, 2011
• Table 7.1 Stem Cell Ancillaries Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
• Table 7.2 Stem Cell Ancillaries Market: Revenues ($m), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
• Table 7.3 Selected Companies Offering Stem Cell-Based Assays, 2012

List of Figures

• Figure 2.1 The Early History of Stem Cell Discovery and Development
• Figure 3.1 Stem Cells Market by Segment: Revenues ($m), Market Shares (%), 2011
• Figure 3.2 Stem Cells Market by Segment: Revenues ($m), 2011-2016
• Figure 3.3 Stem Cells Market by Segment: Revenues ($m), 2017-2022
• Figure 4.1 Stem Cell Therapies Market: Revenues ($m), 2011-2016
• Figure 4.2 Stem Cell Therapies Market: Revenues ($m), 2017-2022
• Figure 4.3 Orthobiologics Market Shares (%), 2011
• Figure 5.1 Quantity of Stem Cell Clinical Trials (All Phases) by Indication, 2012
• Figure 5.2 Oncology Stem Cell Clinical Trials by Phase, 2012
• Figure 5.3 Cardiological/Cardiovascular Stem Cell Clinical Trials by Phase, 2012
• Figure 5.4 Autoimmune, Diabetes, Neurological and Ophthalmological Stem Cell Clinical Trials by Phase, 2012
• Figure 5.5 Pfizer's Stem Cell Collaborations, 2008-2012
• Figure 6.1 Stem Cell Banking Market: Revenues ($m), 2011-2016
• Figure 6.2 Stem Cell Banking Market: Revenues ($m), 2017-2022
• Figure 6.3 Reported Twenty-Year Storage Costs at Various Private Cord Blood Banks Worldwide, 2011
• Figure 7.1 Stem Cell Ancillaries Market: Revenues ($m), 2011-2016
• Figure 7.2 Stem Cell Ancillaries Market: Revenues ($m), 2017-2022
• Figure 7.3 High Profile Toxicity-Related Pharmaceutical Product Withdrawals, 1991-2010
• Figure 7.4 Pharmaceutical R&D Spending by Developmental Stage, 2010
• Figure 10.1 Stem Cell Market Segments: Revenues ($m), 2011-2022

Companies Listed

• 12th Guangzhou Municipal Hospital
• 3DM
• Aastrom Biosciences
• Abbott
• Adistem
• Advanced Cell Technology
• Ageless Regenerative Institute
• AiCuris
• Aldagen
• Alder Biopharmaceuticals
• Alizyme
• AllCells
• Alliancells Bioscience Corporation
• Alliqua
• AlloCure
• American Association of Blood Banks
• Amgen
• Amorcyte
• AM-Pharma
• Amstem Corporation
• Angel Biotechnology
• Angioblast
• Angiotech
• Anterogen
• Antria
• Apatech
• Apceth
• Applied Tissue Technologies
• ArBlast
• Arrow Therapeutics
• Astellas Pharma
• AstraZeneca
• Aurigen Ventures
• Aristotle University of Thessaloniki
• Axcan Pharma
• Arteriocyte
• Athersys
• Axiogenesis
• Banc de Sang i Teixits
• Barts & The London NHS Trust
• Baxter Healthcare
• Bayer
• Beike Biotechnology
• Beth Israel Deaconess Medical Center
• BioE
• Biogenea-Cellgenea
• Biogen Idec
• Bioheart
• Biokine Therapeutics
• BioLife Solutions
• Biologic Therapies
• Bio-Matrix Scientific Group
• BioMet Orthopedics
• BioMimetic Therapeutics
• Biothera
• Biotime
• BrainStorm Cell Therapeutics
• Bresagen
• Cairo University
• California Institute for Regenerative Medicine (CIRM)
• Canadian Blood Services
• Capricor
• Capsant Neurotechnologies
• Cardio3 Bioscience
• Cardiogenesis Corporation
• Celator Pharmaceuticals
• Celgene Corporation
• Cellartis
• CellCentric
• CellCyte Genetics
• Celldex Therapeutics
• Cell Dynamics
• Cellectis
• Cellerant Therapeutics
• Cellerix
• Cell Genesys
• Cellgenia
• CellGenix
• Cell Medica
• Cellonis Biotechnology
• CellSeed
• Cell Therapeutics
• CellTran
• Cellular Dynamics International
• Center for International Blood and Marrow Transplant Research
• Cephalon
• Ceregene
• Cha General Hospital, Seoul
• Chimerix
• Children's Hospital Los Angeles
• Children's Memorial Hospital
• Children's Oncology Group
• China Cord Blood Corporation
• Chinese Academy of Medical Sciences
• Clal Biotechnology Institute
• Cognate BioServices
• Commissie Voor Klinisch Toegepast Onderzoek
• CorCell
• Cord Blood America
• Corestem
• Covance
• Cryo-Cell International
• CryoCord
• Cryo-Save
• CuraGen Corporation
• CyDex Pharmaceuticals
• CyThera
• Cytheris
• Cytomatrix
• Cytori Therapeutics
• CXR Biosciences
• Dana-Farber Cancer Institute
• Denali Ventures
• Dendreon Corporation
• Depuy
• Eastern Cooperative Oncology Group
• Eisai
• Elbit Imaging
• Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA
• Eli Lilly and Company
• Emory University
• Enzon Pharmaceuticals
• EpiStem
• ES Cell International
• European Group for Blood and Marrow Transplantation
• European Medicines Agency (EMEA/EMA)
• European Organization for Research and Treatment of Cancer - EORTC
• Fate Therapeutics
• Food and Drug Administration (US FDA)
• FCB-Pharmicell
• Fibrocell Science
• First Affiliated Hospital of Zhejiang University
• FortiCell Bioscience
• Fred Hutchinson Cancer Research Center
• Fresenius Biotech
• Gamida Cell
• Garnet BioTherapeutics
• General BioTechnology
• General Hospital of Chinese Armed Police Forces
• General Hospital of Guangzhou Military Command of PLA
• Genzyme
• German Low Grade Lymphoma Study Group
• Geron Bio-Med
• Geron Corporation
• Gilead Sciences
• GlaxoSmithKline
• Global Stem
• GMP Unlimited
• Hadassah Medical University
• Hannover Clinical Trial Center
• Harvard Stem Cell Institute (HSCI)
• Harvest Technologies
• Health20 (Zero G Cosmeceuticals)
• Heinrich Heine University, Dusseldorf
• HepaLife Technologies
• Histogen
• HomeoTherapy
• Human Fertilisation and Embryology Authority (HFEA)
• ImmunoCellular Therapeutics
• Immunovative Therapies
• Incyte
• IntelliCell Biosciences
• International Stem Cell Corporation
• International Stemcell Services
• InSCeption Biosciences
• Instituto de Cardiologia do Rio Grande do Sul
• Intercytex
• Intermountain Health Care
• iPierian
• iPS Academia Japan
• Isolagen
• Israel Healthcare Venture
• Israel Stem Cell Society
• Ixion Biotechnology
• Johann Wolfgang Goethe University Hospital
• Johnson & Johnson
• Kiadis Pharma
• Kilburn & Strode LLP
• King's College London
• Korea Food and Drug Administration
• Korea Stem Cell Bank
• Leeds Cancer Centre at St. James's University Hospital
• Licensing Solutions
• LifebankUSA
• Lifebank Cryogenics
• Life Cell
• LifeStem International
• Liu Hua Qiao Hospital
• Lonza
• MacroPore Biosurgery
• Magnafix
• MaRS Innovation
• Masonic Cancer Center, University of Minnesota
• Massachusetts General Hospital
• Maxcyte
• Mayo Clinic
• M.D. Anderson Cancer Center
• MD Biosciences
• Medac
• MedCell Bioscience
• Medipost
• MedImmune
• Medistem
• Medizinische Klinik Mannheim
• Medtronic
• Merck & Co.
• Merck Millipore
• Meshalkin Research Institute of Pathology of Circulation
• Mesoblast
• MG Biotherapeutics
• Miltenyi Biotec
• Ministry of Health, Labour and Welfare (MHLW, Japan)
• MK Alliance
• Molecular Insight Pharmaceuticals
• MolMed
• Monash University
• Monet Medical
• Moorfields Eye Hospital
• Mount Sinai Hospital
• MultiCell Technologies
• Nagoya University
• National Cancer Institute
• National Heart Institute, Mexico
• National Heart, Lung and Blood Institute (NHLB)
• National Institute of Allergy and Infectious Diseases (NIAID)
• Nippon Zoki Pharmaceutical
• National Marrow Donor Program, US
• Neostem
• Neuralstem
• NeuroGeneration
• Northern Therapeutics
• North West Development Agency
• Novartis
• NovaThera - part of MedCell Bioscience
• Novocell
• Noxxon Pharma
• NsGene
• NuVasive
• Odontis
• Oligene
• Opexa Therapeutics
• OrbusNeich
• Organogenesis
• Orthofix
• Osiris Therapeutics
• Osteotech
• Otsuka Pharmaceutical Development & Commercialization
• Ottawa Hospital Research Institute
• Parkinson's UK
• PDL BioPharma
• Pfizer
• Pharmastem Therapeutics
• Pierre Fabre Medicament
• Plasticell
• Pluristem Therapeutics
• Polyphor
• Poniard Pharmaceuticals
• Postgraduate Institute of Medical Education and Research
• Progencell
• Progenitor Cell Therapies
• Proneuron Biotechnologies
• Quintiles
• Rafa Laboratories
• Rambam Health Care Campus
• Regenavita
• Regenerative Medicine Institute of Tijuana
• Regenerative Sciences
• RegeneRx Biopharmaceuticals
• Regenetech
• RegenTec
• Regimmune
• ReInnervate
• Reliance Life Sciences
• ReNeuron
• Renovo
• RenovoCyte
• Renovo Neural
• Reproductive Genetics Institute
• RhinoCyte
• Ribozyome
• RNL Bio Company
• Roche
• Roslin Cellab
• RTI Biologics
• Samsung Medical Center
• SanBio
• Saneron CCEL Therapeutics
• Scorpion Medical
• Scottish Cancer Therapy Network
• S-Evans Biosciences
• Shanghai Jiao Tong University School of Medicine
• Shenzhen Beike Bio-Technology
• Shenzhen Zhongxing Yangfan Biotech
• Skye Orthobiologics
• Southwest Oncology Group
• Spectrum Pharmaceuticals
• Spinesmith Partners
• State Food and Drug Administration (China)
• Stem Cell Authority
• StemCells
• Stem Cell Innovations
• Stem Cell Research Center of Peking University
• Stem Cell Sciences
• StemCell Services
• Stem Cell Therapeutics
• StemCell Technologies
• StemCore
• StemCore Laboratories
• StemCyte
• Stemedica Cell Technologies
• Stemgent
• Stemina Biomarker Discovery
• Stempath
• Stempeutics Research
• Stemride International
• St Jude Children's Research Hospital
• St Mark's Hospital Foundation
• St Theresa's Hospital, Bangalore
• Swedish Orphan Biovitrum
• Swiss Group for Clinical Cancer Research
• Systemix
• TaiGen Biotechnology
• TAP Pharmaceutical Products
• Tarix Pharmaceuticals
• TCA Cellular Therapy
• Technological Park of Ioannina
• Technology Strategy Board of the UK Government
• Tehran University of Medical Sciences
• Tel Aviv University
• Tengion
• Terumo
• Teva Pharmaceutical Industries
• Theradigm
• Therakos
• TheraVitae
• Theratechnologies
• ThermoFisher Scientific
• ThermoGenesis
• TiGenix
• Tissue Genesis
• Tissue Regeneration Technologies
• Titan Pharmaceuticals
• TotipotentRX Cell Therapy
• Toucan Capital
• Transition Therapeutics
• University College London
• Tristem
• Tarix Pharmaceuticals
• Third Military Medical University
• UK Stem Cell Bank
• University College London
• University Hospital, Caen
• University Hospital Carl Gustav Carus
• University Hospital, Limoges
• University of Heidelberg
• University of Kyoto
• University of North Carolina
• University of Queensland
• University of Wisconsin
• Vesta Therapeutics
• VetCell
• ViaCell
• ViaCord
• ViaCyte
• Vical
• Vion Pharmaceuticals
• ViraCor Laboratories
• ViroMed
• ViroPharma
• Vistagen Therapeutics
• Vitro Biopharma
• Vitro Diagnostics
• Weizmann Institute of Science
• WiCell
• Xiamen Amoytop Biotech
• Xcyte Therapies
• XOMA
• Yonsei University
• Zhejiang Armed Police Hospital
• Zhejian First People's Hospital

「世界の幹細胞技術市場展望：2012年〜2022年」は2012年05月23日にビジョンゲインより発行されました。 当レポートは202 Pagesで構成され、税抜￥283,048より販売しています。